vorapaxar and Kidney-Diseases

vorapaxar has been researched along with Kidney-Diseases* in 1 studies

Trials

1 trial(s) available for vorapaxar and Kidney-Diseases

ArticleYear
Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function.
    Journal of thrombosis and thrombolysis, 2019, Volume: 47, Issue:3

    Patients with renal disease are often undertreated with antiplatelet therapy due to concerns about bleeding. Vorapaxar blocks platelet activation via the PAR-1 receptor and reduces cardiovascular events in patients with stable atherosclerosis, but with increased bleeding. We examined the efficacy and safety of vorapaxar in patients with impaired renal function. TRA2°P-TIMI 50 randomized patients with stable atherosclerosis to vorapaxar or. We analyzed patients with eGFR assessed who qualified with a history of MI or PAD (without stroke or TIA) (n = 19,932). Cox models assessed the risk of CV events and bleeding by quartile of baseline eGFR in the placebo arm and then by randomized assignment. Net clinical outcome (NCO) was predefined as CV death, MI, stroke, or GUSTO severe bleeding. Patients with lower eGFR tended to be older, female, have hypertension, hyperlipidemia or prior PAD. In the placebo arm, baseline eGFR in the lowest quartile was associated with a 26% higher risk of CV death, MI or stroke (Q1:Q4 HR

    Topics: Aged; Atherosclerosis; Cardiovascular Diseases; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney Diseases; Lactones; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyridines; Receptor, PAR-1; Risk; Secondary Prevention; Treatment Outcome

2019